Aerpio Comes to the 'Rescue' With HPTP-beta Drug for DME
Flush with $27 million from a Series A in August, Aerpio Therapeutics Inc. is moving full speed ahead into its clinical development program for AKB-9778, a first-in-class human protein tyrosine phosphatase-beta (HPTP-beta) inhibitor, with dosing of the first patients in a Phase Ib/IIa study in diabetic macular edema (DME).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST